Capillary Technologies India Limited reports Q2 FY27 results and appoints new internal auditor

Capillary Technologies India Limited has announced the outcome of its Board Meeting held on November 02, 2026. The Board considered and approved the unaudited financial results for the quarter and half-year ended September 30, 2026. Key highlights include a standalone profit of ₹294.31 million for the quarter and a consolidated profit of ₹219.16 million for the same period. Additionally, the company appointed M/s. Deloitte Touche Tohmatsu India LLP as its new Internal Auditor, effective November 02, 2026.

Financial Performance for Q2 FY27

Capillary Technologies India Limited disclosed its financial results for the second quarter and half-year ended September 30, 2026. On a standalone basis, the company reported a profit of ₹294.31 million for the quarter, a significant increase from the previous year. The half-year standalone profit stood at ₹294.31 million. For the consolidated results, the profit for the quarter ended September 30, 2026, was ₹219.16 million, and the consolidated profit for the half-year was also ₹219.16 million.

Key Financial Figures

The standalone revenue from operations for the quarter was ₹842.58 million, contributing to a total income of ₹881.06 million. Total expenses for the quarter were ₹468.11 million. The consolidated revenue from operations reached ₹2,713.55 million for the quarter, with total income amounting to ₹2,774.14 million and total expenses at ₹2,318.77 million.

Change in Internal Auditor

In a significant corporate development, the Board of Directors also approved the appointment of M/s. Deloitte Touche Tohmatsu India LLP as the new Internal Auditor of the Company. This appointment is effective from November 02, 2026, replacing M/s. Protiviti India Member Private Limited. The Board cited the growing scale and international operations of the company as reasons for engaging a firm with a global network and specialized expertise in internal audit.

Trading Window Closure

Further to previous intimations, the trading window for dealing in the Company’s securities remains closed from October 01, 2026, and will reopen 48 hours after the declaration of financial results. The Board Meeting commenced at 10:00 AM (IST) and concluded at 11:40 AM (IST) on November 02, 2026.

Source: BSE

Previous Article

AstraZeneca Pharma India gets interim relief from overcharging demand

Next Article

Muthoot Finance reports 42% consolidated loan AUM growth and 39% profit increase